Diagnosis and Management of Kawasaki Disease | AAFP
Kawasaki Disease in Infants & Young Children - HealthyChildren.org
Lightning Learning: Kawasaki Disease — EM3
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease | Circulation
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Treatment of Kawasaki disease | Download Table
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
![PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8f3d0e9bcb78fb7089e50d6f77d0efc0737cd69/5-Figure1-1.png "PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar")
PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar
Diagnosis and Management of Kawasaki Disease | AAFP
Frontiers | Kawasaki Disease
Understanding Kawasaki Disease
Kawasaki Disease: Signs, Symptoms and Diagnosis | American Heart Association
Kawasaki Disease: An Update on Diagnosis and Treatment - ScienceDirect
Kawasaki Disease Symptoms | Kawasaki Kids Foundation
Treatment Options for Refractory Kawasaki Disease
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
Kawasaki Disease From COVID-19 in Kids: How Common? | MedPage Today
